Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | POLQ | O75417 | 14/20 | 0.48 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25309592 | 0.88 | POLQ (0.50) | DHODHPOLQ | |
| SCHEMBL7899073 | 0.83 | DHODH (0.56) | DHODHEIF4EBTK | |
| SCHEMBL22717424 | 0.81 | POLQ (0.60) | DHODHPOLQ | |
| SCHEMBL29574532 | 0.81 | POLQ (0.60) | DHODHPOLQ | |
| SCHEMBL29575107 | 0.81 | POLQ (0.60) | DHODHPOLQ | |
| SCHEMBL24501328 | 0.80 | KDM4E (0.44) | DHODHPOLQ | |
| SCHEMBL29695223 | 0.80 | KDM4E (0.44) | DHODHPOLQ | |
| SCHEMBL24770211 | 0.79 | POLQ (0.60) | POLQ | |
| SCHEMBL30016080 | 0.79 | POLQ (0.60) | POLQ | |
| SCHEMBL30905040 | 0.78 | POLQ (0.45) | POLQFFAR4GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | US | disclosed |
| EP-4464709-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118525025-A | Six-membered cyclothiazole compound and application thereof | 南京再明医药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023134739-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | 南京再明医药有限公司 | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | POLRMT, POLQ, POLH | DHODH 236/4885POLQ 2/4885EIF4E 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.